You are here

Tissue Engineering and Regenerative Medicine for COVID‐19

The novel coronavirus disease (COVID‐19) pandemic has significantly impacted tissue engineering and regenerative medicine communities/industries. In a new Perspective article published in STEM CELLS Translational Medicine, researchers led by Abbas Shafiee (University of Queensland, Brisbane, Queensland, Australia) highlight the impact of the recent pandemic on the present and future of tissue engineering and regenerative medicine research and therapies. Furthermore, the authors discuss how tissue engineering may provide three‐dimensional platforms to study disease progression and test the effects of antiviral agents and the benefits and risks of mesenchymal stem cell therapy for COVID‐19 treatment.